CA2667812A1 - Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication - Google Patents

Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication Download PDF

Info

Publication number
CA2667812A1
CA2667812A1 CA 2667812 CA2667812A CA2667812A1 CA 2667812 A1 CA2667812 A1 CA 2667812A1 CA 2667812 CA2667812 CA 2667812 CA 2667812 A CA2667812 A CA 2667812A CA 2667812 A1 CA2667812 A1 CA 2667812A1
Authority
CA
Canada
Prior art keywords
intron
polymorphism
seq
patients
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2667812
Other languages
English (en)
French (fr)
Inventor
Francis J. Mcmahon
Gonzalo E. Laje
Silvia Paddock
Husseini K. Manji
A. John Rush
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
US Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2667812A1 publication Critical patent/CA2667812A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA 2667812 2006-10-27 2007-10-26 Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication Abandoned CA2667812A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85497806P 2006-10-27 2006-10-27
US60/854,978 2006-10-27
PCT/US2007/082683 WO2008052167A2 (en) 2006-10-27 2007-10-26 Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication

Publications (1)

Publication Number Publication Date
CA2667812A1 true CA2667812A1 (en) 2008-05-02

Family

ID=39276298

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2667812 Abandoned CA2667812A1 (en) 2006-10-27 2007-10-26 Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication

Country Status (5)

Country Link
US (2) US7906283B2 (https=)
EP (1) EP2087136A2 (https=)
JP (1) JP2010508029A (https=)
CA (1) CA2667812A1 (https=)
WO (1) WO2008052167A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166112B1 (en) 2008-09-18 2013-06-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for diagnosing predisposition for treatment emergent suicidal ideation
CA2736936A1 (en) 2008-09-18 2010-03-25 Andreas Menke Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (tesi)
CA2918054C (en) * 2013-07-11 2022-12-13 The Johns Hopkins University A dna methylation and genotype specific biomarker of suicide attempt and/or suicide ideation
US11122997B2 (en) 2015-04-17 2021-09-21 Mayo Foundation For Medical Education And Research Modulating the aryl hydrocarbon receptor system to treat major depressive disorder
CA2891830A1 (en) 2015-05-15 2016-11-15 Centre For Addiction And Mental Health Genetic markers for suicide risk and related methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1410036A2 (en) 2001-01-19 2004-04-21 Mindsense Biosystems Ltd. Methods and compositions for diagnosing and treating a subject having depression
US7083921B2 (en) 2001-08-29 2006-08-01 The Board Of Trustees Of The Leland Stanford Junior University Method to determine the risk for side effects of an SSRI treatment in a person
JP5348840B2 (ja) 2003-02-20 2013-11-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 薬物を選択する方法
WO2004103394A2 (en) * 2003-05-15 2004-12-02 University Of Chicago Method and compositions for nerve regeneration
US20050069936A1 (en) 2003-09-26 2005-03-31 Cornelius Diamond Diagnostic markers of depression treatment and methods of use thereof
US20060160119A1 (en) 2005-01-14 2006-07-20 Barbara Turner Genetic screening for improving treatment of patients diagnosed with depression
US20080299125A1 (en) 2006-06-05 2008-12-04 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients

Also Published As

Publication number Publication date
WO2008052167A2 (en) 2008-05-02
EP2087136A2 (en) 2009-08-12
US20080102467A1 (en) 2008-05-01
US7906283B2 (en) 2011-03-15
JP2010508029A (ja) 2010-03-18
WO2008052167A3 (en) 2008-11-13
US20110118133A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
Kohen et al. Association of serotonin transporter gene polymorphisms with poststroke depression
US7795033B2 (en) Methods to predict the outcome of treatment with antidepressant medication
WO2013160315A2 (en) Genetic predictors of response to treatment with crhr1 antagonists
US7906283B2 (en) Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication
US20110086777A1 (en) Method for autism prediction
JP2020089370A (ja) 抗精神病薬に基づく処置により誘導される錐体外路症状（ｅｐｓ）の発症を予測する方法
US20110091899A1 (en) Combination of risk alleles associated with autism
AU2004213582A1 (en) Methods for the prediction of suicidality during treatment
Anitha et al. Gene and expression analyses reveal enhanced expression of pericentrin 2 (PCNT2) in bipolar disorder
Seal et al. Segmental uniparental isodisomy on 5q32-qter in a patient with childhood-onset schizophrenia
AU2005250142B2 (en) Biomarkers for the prediction of responsiveness to clozapine treatment
US20100003691A1 (en) Genetic Markers Associated with Degenerative Disc Disease and Uses Thereof
US10731219B1 (en) Method for preventing progression to metabolic syndrome
US20140045717A1 (en) Single Nucleotide Polymorphism Biomarkers for Diagnosing Autism
US20060177860A1 (en) Genetic markers in the HLA-DQBI gene associated with an adverse hematological response to drugs
WO2009101619A2 (en) Methods for predicting a patient's response to lithium treatment
Torres Highly Penetrant Alterations of a Critical Region Including BDNF in Human Psychopathology and Obesity
Amstadter et al. Selected summaries from the XVII World Congress of Psychiatric Genetics, San Diego, California, USA, 4–8 November 2009
Hayden et al. Genetics of bipolar disorder
Cavalleri Haplotype mapping in epilepsy genetics and pharmacogenetics
WO2009036513A1 (en) Diagnostic and therapeutic protocols
WO2011045402A1 (en) Autism-associated functional polymorphisms in slc25a12 gene

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20131028